LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Nektar Therapeutics

Uždarymo kaina

0.66

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.65

Max

0.69

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-58M

-51M

Pardavimai

-19M

10M

Pelnas, tenkantis vienai akcijai

-0.24

Pelno marža

-486.444

Darbuotojai

61

EBITDA

-62M

-45M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+613.04% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.7M

129M

Ankstesnė atidarymo kaina

0.66

Ankstesnė uždarymo kaina

0.66

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Nektar Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-20 20:54; UTC

Įsigijimai, susijungimai, perėmimai

PNC to Buy Private-Equity Agent Aqueduct Capital

2025-05-20 20:50; UTC

Uždarbis

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

2025-05-20 23:48; UTC

Įsigijimai, susijungimai, perėmimai

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

2025-05-20 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

2025-05-20 23:39; UTC

Rinkos pokalbiai

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

2025-05-20 23:08; UTC

Rinkos pokalbiai

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

2025-05-20 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

2025-05-20 22:45; UTC

Įsigijimai, susijungimai, perėmimai

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

2025-05-20 22:44; UTC

Svarbiausios naujienos

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

2025-05-20 22:20; UTC

Svarbiausios naujienos

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

2025-05-20 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

2025-05-20 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q EPS 34c >ZTO

2025-05-20 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

2025-05-20 21:44; UTC

Uždarbis

James Hardie Industries 4Q Adj EPS 36c >JHX

2025-05-20 21:44; UTC

Uždarbis

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

2025-05-20 21:44; UTC

Uždarbis

James Hardie Industries 4Q EPS 10c >JHX

2025-05-20 21:44; UTC

Uždarbis

James Hardie Industries 4Q Sales $972M >JHX

2025-05-20 20:52; UTC

Svarbiausios naujienos

Elon Musk to Cut Back Political Spending -- 3rd Update

2025-05-20 20:52; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-20 20:52; UTC

Rinkos pokalbiai

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

2025-05-20 20:30; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

2025-05-20 20:28; UTC

Įsigijimai, susijungimai, perėmimai

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

2025-05-20 20:23; UTC

Įsigijimai, susijungimai, perėmimai

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

2025-05-20 20:22; UTC

Uždarbis

XP 1Q Adj EPS BRL2.29 >XP

2025-05-20 20:22; UTC

Uždarbis

XP 1Q Rev BRL4.345B >XP

2025-05-20 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

2025-05-20 20:20; UTC

Svarbiausios naujienos

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

2025-05-20 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

2025-05-20 20:11; UTC

Svarbiausios naujienos

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

2025-05-20 20:09; UTC

Uždarbis

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Akcijų palyginimas

Kainos pokytis

Nektar Therapeutics Prognozė

Kainos tikslas

By TipRanks

613.04% į viršų

12 mėnesių prognozė

Vidutinis 4.92 USD  613.04%

Aukščiausias 7 USD

Žemiausias 2 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Nektar Therapeutics kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

6

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

0.5949 / 0.7406Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.